EXHIBIT 2
US ONCOLOGY, INC.
$175,000,000 9 5/8% Senior Subordinated Notes due 2012
PURCHASE AGREEMENT
January 25, 2002
New York, New York
UBS Warburg LLC
299 Park Avenue
New York, New York 10171
Deutsche Banc Alex. Brown Inc.
31 West 52nd Street
New York, New York 10019
First Union Securities, Inc.
12 East 49th Street, 44th Floor
New York, New York 10017
Ladies and Gentlemen:
US Oncology, Inc., a Delaware corporation (the "Company"), and
each of the Guarantors (as defined herein), agree with you as follows:
1. Issuance of Notes. The Company proposes to issue and sell
-----------------
to UBS Warburg LLC, Deutsche Banc Alex. Brown Inc. and First Union Securities,
Inc. (the "Initial Purchasers") $175,000,000 aggregate principal amount of 9
5/8% Senior Subordinated Notes due 2012 (the "Original Notes"). The Original
Notes will be issued pursuant to an indenture (the "Indenture"), to be dated the
Closing Date (as defined herein), by and among the Company, the Guarantors and
JP Morgan Chase Bank, as trustee (the "Trustee"). The Company's obligations
under the Original Notes will be unconditionally guaranteed (the "Guarantees")
on an unsecured senior subordinated basis by the guarantors listed on Schedule I
----------
hereto (collectively, the "Guarantors" and, collectively with the Company, the
"Issuers"). All references herein to the Original Notes include the related
Guarantees, unless the context otherwise requires. Capitalized terms used but
not otherwise defined herein shall have the meanings given to such terms in the
Indenture.
The Original Notes will be offered and sold to the Initial
Purchasers pursuant to an exemption from the registration requirements under the
Securities Act of 1933, as amended (the "Act"). The Issuers have prepared a
preliminary offering memorandum, dated January 9, 2002 (together with any
amendments or supplements thereto, the "Preliminary Offering Memorandum"),
-2-
and a final offering memorandum dated and available for distribution on the date
hereof (together with any amendments or supplements thereto, the "Offering
Memorandum") relating to the Company, the Guarantors and the Original Notes.
The Initial Purchasers have advised the Company that the
Initial Purchasers intend, as soon as they deem practicable after this Purchase
Agreement (this "Agreement") has been executed and delivered, to resell (the
"Exempt Resales") the Original Notes purchased by the Initial Purchasers under
this Agreement in private sales exempt from registration under the Act on the
terms set forth in the Offering Memorandum, as amended or supplemented, solely
to (i) persons whom the Initial Purchasers reasonably believe to be "qualified
institutional buyers," as defined in Rule 144A under the Act ("QIBs"), and (ii)
other eligible purchasers pursuant to offers and sales that occur outside the
United States within the meaning of Regulation S under the Act; the persons
specified in clauses (i) and (ii) are sometimes collectively referred to herein
as the "Eligible Purchasers."
Upon issuance of the Original Notes and until such time as the
same is no longer required under the applicable requirements of the Act, the
Original Notes shall bear the legend relating thereto set forth under "Notice to
Investors" in the Offering Memorandum.
Holders (including subsequent transferees) of the Original
Notes will have the registration rights set forth in the registration rights
agreement (the "Registration Rights Agreement") to be dated the Closing Date in
form and substance reasonably satisfactory to the Initial Purchasers and
conforming to the description thereof in the Offering Memorandum, for so long as
such Original Notes constitute "Registrable Notes" (as defined in the
Registration Rights Agreement). Pursuant to the Registration Rights Agreement,
the Issuers will agree to (i) file with the Securities and Exchange Commission
(the "Commission") under the circumstances set forth in the Registration Rights
Agreement, (a) a registration statement under the Act (the "Exchange Offer
Registration Statement") relating to a new issue of debt securities
(collectively with the Private Exchange Notes (as defined in the Registration
Rights Agreement), the "Exchange Notes" and, together with the Original Notes,
the "Notes," which term includes the guarantees related thereto) to be offered
in exchange for the Original Notes (the "Exchange Offer") and issued under the
Indenture or an indenture substantially identical to the Indenture and/or (b)
under certain circumstances set forth in the Registration Rights Agreement, a
shelf registration statement pursuant to Rule 415 under the Act (the "Shelf
Registration Statement" and, together with the Exchange Offer Registration
Statement, the "Registration Statements") relating to the resale by certain
holders of the Original Notes, and (ii) to use their commercially reasonable
best efforts to cause such Registration Statements to be declared effective.
This Agreement, the Notes, the Indenture and the Registration Rights Agreement
are hereinafter sometimes referred to collectively as the "Note Documents."
The Original Notes are being offered and sold by the Company
in part combined with the financings under the Credit Facilities (defined below)
to (i) refinance the Company's existing $175.0 million senior credit facility
(the "Debt Refinancing"), (ii) terminate and repay in full the Company's
existing lease financing facility, (iii) repay in full the Company's existing
$100.0 million Senior Notes due 2006, (iv) provide for the Company's ongoing
working capital needs and other general corporate purposes and (v) pay related
transaction fees and expenses. In addition, the Company will enter into a Credit
Agreement (the "Credit Agreement") and an Amended and Restated Participa-
-3-
tion Agreement (collectively, the "Credit Facilities") with First Union
Securities, Inc. as agent, and certain lenders thereto whereby the Company will
have no less than a $87.981968 million senior credit facility and a $72.018032
million master operating lease available.
The offering of the Original Notes, the Debt Refinancing and
the entering into of the Credit Facilities on the Closing Date (as defined
below) are collectively referred to as the "Transactions." The Note Documents,
the Credit Facilities and the Credit Documents (as defined in the Credit
Agreement) are collectively referred to herein as the "Transaction Documents."
2. Agreements to Sell and Purchase. On the basis of the
-------------------------------
representations, warranties and covenants contained in this Agreement, and
subject to the terms and conditions contained in this Agreement, the Issuers
agree to issue and sell to the Initial Purchasers, and the Initial Purchasers
agree to purchase from the Issuers, the aggregate principal amount of the
Original Notes set forth opposite their respective names in Schedule III hereto.
The purchase price for the Original Notes shall be 97.25% of their principal
amount.
3. Delivery and Payment. Delivery of, and payment of the
--------------------
purchase price for, the Original Notes shall be made at 10:00 a.m., New York
City time, on February 1, 2001 (such date and time, the "Closing Date") at the
offices of Cahill Gordon & Reindel at 80 Pine Street, New York, New York 10005.
The Closing Date and the location of delivery of and the form of payment for the
Original Notes may be varied by mutual agreement between the Initial Purchasers
and the Company.
One or more of the Original Notes in global form registered in
such names as the Initial Purchasers may request upon at least one business
day's notice prior to the Closing Date and having an aggregate principal amount
corresponding to the aggregate principal amount of the Original Notes shall be
delivered by the Company to the Initial Purchasers (or as the Initial Purchasers
direct), against payment by the Initial Purchasers of the purchase price
therefor by means of transfer of immediately available funds to such account or
accounts specified by the Company in accordance with its obligations under
Sections 4(g) and 8(a)(xii) hereof on or prior to the Closing Date, or by such
means as the parties hereto shall agree prior to the Closing Date.
4. Agreements of the Issuers. The Issuers, jointly and
-------------------------
severally, covenant and agree with the Initial Purchasers as follows:
(a) To furnish the Initial Purchasers and those persons identified by the
Initial Purchasers, without charge, with as many copies of the Preliminary
Offering Memorandum and the Offering Memorandum, and any amendments or
supplements thereto, as the Initial Purchasers may reasonably request. The
Issuers consent to the use in accordance with the provisions of the Act and with
securities or "blue sky" laws of the jurisdictions in which the Notes are
offered of the Preliminary Offering Memorandum and the Offering Memorandum, and
any amendments and supplements thereto required pursuant to this Agreement, by
the Initial Purchasers in connection with Exempt Resales.
(b) Not to amend or supplement the Offering Memorandum prior to the Closing
Date unless the Initial Purchasers shall previously have been advised of, and
shall not have
-4-
reasonably objected to, such amendment or supplement within a reasonable time,
but in any event not longer than two business days after being furnished with a
copy of such amendment or supplement.
(c) If, during the time that an Offering Memorandum is required to be
delivered in connection with any Exempt Resales after the date of this Agreement
and prior to the consummation of the Exchange Offer, any event shall occur that,
in the judgment of the Issuers or in the judgment of counsel to the Initial
Purchasers, makes any statement of a material fact in the Offering Memorandum,
as then amended or supplemented, untrue or that requires the making of any
additions to or changes in the Offering Memorandum in order to make the
statements in the Offering Memorandum, as then amended or supplemented, in the
light of the circumstances under which they are made, not misleading, or if it
is necessary to amend or supplement the Offering Memorandum to comply with all
applicable laws, the Issuers shall promptly notify the Initial Purchasers of
such event and prepare an appropriate amendment or supplement to the Offering
Memorandum so that (i) the statements in the Offering Memorandum, as amended or
supplemented, will, in the light of the circumstances at the time that the
Offering Memorandum is delivered to prospective Eligible Purchasers, not be
misleading and (ii) the Offering Memorandum will comply with applicable law.
(d) To cooperate with the Initial Purchasers and counsel to the Initial
Purchasers in connection with the qualification or registration of the Original
Notes under the securities laws of such jurisdictions as the Initial Purchasers
may request and to continue such qualification in effect so long as required for
the Exempt Resales. Notwithstanding the foregoing, no Issuer shall be required
to qualify as a foreign corporation in any jurisdiction in which it is not so
qualified or to file a general consent to service of process in any such
jurisdiction or subject itself to any taxation in any such jurisdiction where it
is not then so subject.
(e) To advise the Initial Purchasers promptly and, if requested by the
Initial Purchasers, to confirm such advice in writing, of the issuance by any
securities commission of any stop order suspending the qualification or
exemption from qualification of any of the Original Notes for offering or sale
in any jurisdiction, or the initiation of any proceeding for such purpose by any
securities commission or other regulatory authority. The Issuers shall use their
commercially reasonable best efforts to prevent the issuance of any stop order
or order suspending the qualification or exemption of any of the Original Notes
under any securities laws, and if at any time any securities commission or other
regulatory authority shall issue an order suspending the qualification or
exemption of any of the Original Notes under any securities laws, the Issuers
shall use their commercially reasonable best efforts to obtain the withdrawal or
lifting of such order at the earliest possible time.
(f) Whether or not the transactions contemplated by this Agreement are
consummated or this Agreement becomes effective or is terminated other than by
reason of a default by the Initial Purchasers, to pay all costs, expenses, fees,
disbursements (including fees, expenses and disbursements of counsel to the
Issuers) reasonably incurred and stamp, documentary or similar taxes incident to
and in connection with: (i) the preparation, printing and distribution of the
Preliminary Offering Memorandum and the Offering Memorandum (in-
-5-
cluding, without limitation, financial statements) and all amendments and
supplements thereto, (ii) all expenses (including travel expenses) of the
Issuers and the Initial Purchasers in connection with any meetings with
prospective investors in the Original Notes, (iii) the preparation, notarization
(if necessary) and delivery of the Note Documents and all other agreements,
memoranda, correspondence and documents prepared and delivered in connection
with this Agreement and with the Exempt Resales, (iv) the issuance, transfer and
delivery by the Company and the Guarantors of the Original Notes and the
Guarantees, respectively, to the Initial Purchasers, (v) the qualification or
registration of the Notes for offer and sale under the securities laws of the
several states of the United States or provinces of Canada (including, without
limitation, the cost of printing and mailing preliminary and final "blue sky" or
legal investment memoranda and fees and disbursements of counsel (including
local counsel) to the Initial Purchasers relating thereto), (vi) the furnishing
of such copies of the Preliminary Offering Memorandum and the Offering
Memorandum, and all amendments and supplements thereto, as may be reasonably
requested for use in connection with Exempt Resales, (vii) the preparation of
certificates for the Notes, (viii) the application for quotation of the Notes in
The Portal Market ("Portal") market of the National Association of Securities
Dealers, Inc. ("NASD"), including, but not limited to, all listing fees and
expenses, (ix) the approval of the Notes by The Depository Trust Company ("DTC")
for "book-entry" transfer, (x) the rating of the Notes by rating agencies, (xi)
the fees and expenses of the Trustee and its counsel and (xii) the performance
by the Issuers of their other obligations under the Note Documents. In addition,
if the transactions contemplated by this agreement are not consummated or this
agreement is terminated other than by reason of a default by the Initial
Purchasers, the Issuer shall pay the fees, expenses and disbursements of counsel
to the Initial Purchasers.
(g) To use the proceeds from the sale of the Original Notes in the manner
described in the Offering Memorandum under the caption "Use of Proceeds."
(h) To do and perform in all material respects all things required to be
done and performed under this Agreement by them prior to or after the Closing
Date and to satisfy all conditions precedent on their part to the delivery of
the Original Notes except to the extent any such condition has been waived in
writing by Initial Purchasers.
(i) Not to, and not to permit any of their subsidiaries to, sell, offer for
sale or solicit offers to buy any security (as defined in the Act) that would be
integrated with the sale of the Original Notes in a manner that would require
the registration under the Act of the sale of the Original Notes to the Initial
Purchasers or any Eligible Purchasers.
(j) Not to permit any Issuer to, and to use their commercially reasonable
best efforts to cause their other affiliates (as defined in Rule 144 under the
Act) not to, resell any of the Original Notes that have been reacquired by any
of them.
(k) Not to engage, not to allow any of their subsidiaries to engage, and to
use their commercially reasonable best efforts to cause their other affiliates
and any person acting on their behalf (other than, in any case, the Initial
Purchasers and any of their affiliates, as to whom the Issuers make no covenant)
not to engage, in any form of general solicitation or gen-
-6-
eral advertising (within the meaning of Regulation D under the Act) in
connection with any offer or sale of the Original Notes in the United
States prior to the effectiveness of a registration statement with respect
to the Notes.
(l) Not to engage, not to allow any of their subsidiaries to engage,
and to use their commercially reasonable best efforts to cause their other
affiliates and any person acting on their behalf (other than, in any case,
the Initial Purchasers and any of their affiliates, as to whom the Issuers
make no covenant) not to engage, in any directed selling effort with
respect to the Original Notes, and to comply with the offering restrictions
requirement of Regulation S under the Act. Terms used in this paragraph
have the meanings given to them by Regulation S.
(m) From and after the Closing Date, for so long as any of the Notes
remain outstanding and are "restricted securities" within the meaning of
Rule 144(a)(3) under the Act and during any period in which the Company is
not subject to Section 13 or 15(d) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act"), to make available upon request the
information required by Rule 144A(d)(4) under the Act to (i) any holder or
beneficial owner of Notes in connection with any sale of such Notes and
(ii) any prospective purchaser of such Notes from any such holder or
beneficial owner designated by the holder or beneficial owner. The Issuers
will pay the expenses of printing and distributing such documents.
(n) To comply with all of their material agreements set forth in the
Registration Rights Agreement.
(o) To comply with all of their obligations set forth in the
representations letter of the Issuers to DTC relating to the approval of
the Notes by DTC for "book-entry" transfer and to use their commercially
reasonable best efforts to obtain approval of the Notes by DTC for
"book-entry" transfer.
(p) To use their commercially reasonable best efforts to effect the
inclusion of the Original Notes in Portal.
(q) Prior to the Closing Date, to furnish without charge to the
Initial Purchasers, (i) as soon as they have been prepared by the Company,
a copy of any regularly prepared final internal financial statements of the
Company and its subsidiaries for any period subsequent to the period
covered by the financial statements appearing in the Offering Memorandum,
(ii) all other reports and other communications (financial or otherwise)
that the Issuers mail or otherwise make available to security holders and
(iii) such other information as the Initial Purchasers shall reasonably
request.
(r) Not to distribute prior to the Closing Date any offering material
in connection with the offer and sale of the Original Notes other than the
Preliminary Offering Memorandum and the Offering Memorandum.
-7-
(s) During the period of two years after the Closing Date or, if
earlier, until such time as the Original Notes are no longer restricted
securities (as defined in Rule 144 under the Act), not to be or become a
closed-end investment company required to be registered, but not
registered, under the Investment Company Act of 1940.
(t) In connection with the offering, until the Initial Purchasers
shall have notified the Company of the completion of the resale of the
Notes, not to, and not to permit any of their affiliates (as such term is
defined in Rule 501(b) of Regulation D under the Act) to, either alone or
with one or more other persons, bid for or purchase for any account in
which they or any of their affiliates have a beneficial interest any Notes;
and none of the Issuers nor any of their affiliates will make bids or
purchases for the purpose of creating actual, or apparent, active trading
in, or of raising the price of, the Notes.
5. Representations and Warranties. (a) The Issuers, jointly and
------------------------------
severally, represent and warrant to the Initial Purchasers that:
(i) Each of the Preliminary Offering Memorandum and the Offering
Memorandum has been prepared for use in connection with the Exempt Resales.
Neither the Preliminary Offering Memorandum nor the Offering Memorandum as
of its respective issue date, and on the Closing Date the Offering
Memorandum, will contain any untrue statement of a material fact or omit to
state any material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not
misleading; provided, however, that the Issuers make no representation or
warranty with respect to information contained in or omitted from the
Preliminary Offering Memorandum or the Offering Memorandum, as supplemented
or amended, in reliance upon and in conformity with the information
furnished to the Company in writing by or on behalf of the Initial
Purchasers relating to the Initial Purchasers expressly for inclusion in
the Preliminary Offering Memorandum, the Offering Memorandum or any
supplement or amendment thereto. No order preventing the use of the
Preliminary Offering Memorandum or the Offering Memorandum, or any order
asserting that any of the transactions contemplated by this Agreement are
subject to the registration requirements of the Act, has been issued or to
the knowledge of the Company or the Subsidiaries, has been threatened.
(ii) The documents incorporated by reference in the Offering
Memorandum heretofore filed with the Commission were filed in a timely
manner and, when they were filed (or, if any amendment with respect to any
such document was filed, when such amendment was filed), conformed in all
material respects to the requirements of the Exchange Act and the rules and
regulations thereunder, and any further incorporated documents so filed
will, when they are filed, conform in all material respects with the
requirements of the Exchange Act and the rules and regulations thereunder;
no such document when it was filed (or, if an amendment with respect to any
such document was filed, when such amendment was filed), contained an
untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary to make the statements therein
not misleading; and no such further document, when it is filed, will
contain an untrue statement of a material fact or will omit to
-8-
state a material fact required to be stated therein or necessary in order
to make the statements therein not misleading.
(iii) There are no securities of the Issuers that are listed on a
national securities exchange registered under Section 6 of the Exchange Act
or that are quoted in a United States automated interdealer quotation
system of the same class as the Notes within the meaning of Rule 144A under
the Act.
(iv) As of the Closing Date, the Company shall have an authorized
capitalization as set forth under the heading "Capitalization" in the
Offering Memorandum. All of the issued and outstanding shares of capital
stock of the Company have been duly authorized and validly issued, are
fully paid and nonassessable and were not issued in violation of any
preemptive or similar rights. Attached hereto as Schedule II is a true and
-----------
complete list of each subsidiary of the Company that would be a
"Significant Subsidiary" as defined in Article 1, Rule 1-02 of Regulation
S-X under the Act, assuming all references to "10 percent" in such
definition are changed to "5 percent," their jurisdictions of incorporation
or formation, type of entity and percentage equity ownership by the Company
(all such Significant Subsidiaries, the "Subsidiaries"). All of the issued
and outstanding shares of capital stock of each of the Company's
Subsidiaries have been duly and validly authorized and issued, are fully
paid and nonassessable, were not issued in violation of any preemptive or
similar rights and, except as set forth in the Offering Memorandum, are
owned by the Company free and clear of all Liens (as defined in the
Indenture) (other than those imposed by the Act, the securities or "blue
sky" laws of certain jurisdictions and pursuant to the Credit Agreement).
Except as set forth in the Offering Memorandum, except for stock options
held by the Company's employees and affiliates, and except for the rights
of affiliated physicians to receive shares of common stock of the Company
in connection with their entering into management services agreements with
the Company, there are no outstanding options, warrants or other rights to
acquire or purchase, or instruments convertible into or exchangeable for,
any shares of capital stock of any of the Company's Subsidiaries. Other
than affiliated physicians who have acquired shares of common stock of the
Company in connection with the Consideration Agreements, no holder of any
securities of the Company or any of the Subsidiaries is entitled to have
such securities (other than the Notes) registered under any registration
statement contemplated by the Registration Rights Agreement or any other
agreement.
(v) Each of the Company and the Subsidiaries (a) is a corporation,
partnership or other entity duly organized and validly existing under the
laws of the jurisdiction of its incorporation or organization, as the case
may be; (b) has all requisite corporate or other power and authority, and
has all governmental licenses, authorizations, consents and approvals,
necessary to own its property and carry on its business as now being
conducted, except if the failure to obtain any such license, authorization,
consent and approval could not reasonably be expected to have a Material
Adverse Effect; and (c) is qualified to do business and is in good standing
in all jurisdictions in which the nature of the business conducted by it
makes such qualification necessary and where failure to be so qualified and
in good standing individually or in the aggregate could reasonably be
expected to have a Material Adverse Effect. A "Material Adverse Effect"
means any material adverse effect on the business, condition financial
-9-
or other, results of operations, performance, properties or prospects of
the Company and its subsidiaries, taken as a whole.
(vi) Each of the Issuers has all requisite corporate or other power
and authority to execute, deliver and perform all of its obligations under
the Transaction Documents to which it is a party and to consummate the
transactions contemplated by the Transaction Documents to be consummated on
its part and, without limitation, the Company has all requisite corporate
power and authority to issue, sell and deliver and perform its obligations
under the Notes and each Guarantor has all requisite corporate or other
power and authority to execute, deliver and perform all its obligations
under its Guarantee.
(vii) This Agreement has been duly and validly authorized, executed
and delivered by each Issuer.
(viii) The Indenture has been duly and validly authorized by each
Issuer and, when duly executed and delivered by each Issuer (assuming the
due authorization, execution and delivery thereof by the Trustee), will be
a legal, valid and binding obligation of each of the Issuers, enforceable
against each of them in accordance with its terms, except as the
enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, fraudulent conveyance, moratorium or other similar laws
affecting the enforcement of creditors' rights generally and by general
principles of equity and the discretion of the court before which any
proceeding therefor may be brought. The Indenture, when executed and
delivered, will conform in all material respects to the description thereof
in the Offering Memorandum.
(ix) The Original Notes have been duly and validly authorized for
issuance and sale to the Initial Purchasers by the Company and, when
issued, authenticated and delivered by the Company against payment by the
Initial Purchasers in accordance with the terms of this Agreement and the
Indenture, the Original Notes will be legal, valid and binding obligations
of the Company, entitled to the benefits of the Indenture and enforceable
against the Company in accordance with their terms, except as the
enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, fraudulent conveyance, moratorium or other similar laws
affecting the enforcement of creditors' rights generally and by general
principles of equity and the discretion of the court before which any
proceeding therefor may be brought. The Original Notes, when issued,
authenticated and delivered, will conform in all material respects to the
description thereof in the Offering Memorandum.
(x) The Exchange Notes have been, or upon the Closing Date will be,
duly and validly authorized for issuance by the Company and, when issued,
authenticated and delivered by the Company in accordance with the terms of
the Registration Rights Agreement, the Exchange Offer and the Indenture,
the Exchange Notes will be legal, valid and binding obligations of the
Company, entitled to the benefits of the Indenture and enforceable against
the Company in accordance with their terms, except as the enforcement
thereof may be limited by bankruptcy, insolvency, reorganization,
fraudulent conveyance, moratorium or other similar laws affecting the
enforcement of creditors' rights generally and by general principles of
equity and the discretion of the court before which any proceeding therefor
may be brought.
-10-
(xi) The Guarantees have been duly and validly authorized by the
Guarantors and, when the Original Notes are issued, authenticated and
delivered by the Company against payment by the Initial Purchasers in
accordance with the terms of this Agreement and the Indenture, will be
legal, valid and binding obligations of the Guarantors, enforceable against
each of them in accordance with their terms, except as the enforcement
thereof may be limited by bankruptcy, insolvency, reorganization,
fraudulent conveyance, moratorium or other similar laws affecting the
enforcement of creditors' rights generally and by general principles of
equity and the discretion of the court before which any proceeding therefor
may be brought. The Guarantees, when executed and delivered, will conform
in all material respects to the description thereof in the Offering
Memorandum.
(xii) The guarantees to be endorsed on the Exchange Notes have been
duly and validly authorized by the Guarantors and, when the Exchange Notes
are issued, authenticated and delivered in accordance with the terms of the
Registration Rights Agreement, the Exchange Offer and the Indenture, will
be legal, valid and binding obligations of the Guarantors, enforceable
against each of them in accordance with their terms, except as the
enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, fraudulent conveyance, moratorium or other similar laws
affecting the enforcement of creditors' rights generally and by general
principles of equity and the discretion of the court before which any
proceeding therefor may be brought.
(xiii) The Registration Rights Agreement has been duly and validly
authorized by each of the Issuers and, when duly executed and delivered by
each of the Issuers (assuming the due authorization, execution and delivery
thereof by the Initial Purchasers), will constitute a legal, valid and
binding obligation of each of the Issuers, enforceable against them in
accordance with its terms, except that (A) the enforcement thereof may be
subject to (i) bankruptcy, insolvency, reorganization, moratorium or other
similar laws now or hereafter in effect relating to the enforcement of
creditors' rights generally and (ii) general principles of equity and the
discretion of the court before which any proceeding therefor may be brought
and (B) any rights to indemnity or contribution thereunder may be limited
by federal and state securities laws and public policy considerations. The
Registration Rights Agreement will conform in all material respects to the
description thereof in the Offering Memorandum.
(xiv) The Credit Facilities have been duly and validly authorized by
the Company and its Subsidiaries and, when executed and delivered by the
Company and each Subsidiary (assuming the due authorization, execution and
delivery by the other parties thereto), will be legal, valid and binding
obligations of the Company and the Subsidiaries, enforceable against each
of them in accordance with its terms, except that (A) the enforcement
thereof may be subject to (i) bankruptcy, insolvency, reorganization,
moratorium or other similar laws now or hereafter in effect relating to
creditors' rights generally, and (ii) general principles of equity and the
discretion of the court before which any proceeding therefor may be brought
and (B) any rights to indemnity or contribution thereunder may be limited
by federal and state securities laws and public policy considerations. The
Credit Facilities, when executed and delivered, will conform in all
material respects to the description thereof in the Offering Memorandum.
-11-
(xv) All taxes, fees and other governmental charges that are
due and payable on or prior to the Closing Date in connection with the
execution, delivery and performance of the Note Documents and the
execution, delivery and sale of the Original Notes shall have been paid
by or on behalf of the Company at or prior to the Closing Date.
(xvi) None of the Company or the Subsidiaries is (A) in
violation of its charter, bylaws or other constitutive documents, (B)
in default (or, with notice or lapse of time or both, would be in
default) in the performance or observance of any obligation, agreement,
covenant or condition contained in any bond, debenture, note,
indenture, mortgage, deed of trust, loan or credit agreement, lease,
license, franchise agreement, authorization, permit, certificate or
other agreement or instrument to which any of them is a party or by
which any of them is bound or to which any of their assets or
properties is subject (collectively, "Agreements and Instruments"), or
(C) in violation of any law, statute, rule, regulation, judgment, order
or decree of any domestic or foreign court with jurisdiction over any
of them or any of their assets or properties or other governmental or
regulatory authority, agency or other body, which, in the case of
clauses (B) and (C) herein, would reasonably be expected to have,
either individually or in the aggregate, a Material Adverse Effect.
There exists no condition that, with notice or the passage of time
would constitute a default by the Company or the Subsidiaries under any
such document or instrument or result in the imposition of any penalty
or the acceleration of any indebtedness, other than penalties, defaults
or conditions that would not have a Material Adverse Effect.
(xvii) The execution, delivery and performance by each of the
Issuers of the Transaction Documents to which they are a party
including the consummation of the offer and sale of the Original Notes
does not or will not violate, conflict with or constitute a breach of
any of the terms or provisions of or a default under (or an event that
with notice or the lapse of time, or both, would constitute a default),
or require consent under, or result in the creation or imposition of a
lien, charge or encumbrance on any property or assets of any of the
Company or any Subsidiary (other than as created pursuant to the Credit
Facilities) or an acceleration of any indebtedness of the Company or
any Subsidiary pursuant to, (i) the charter, bylaws or other
constitutive documents of any of the Company or any Subsidiary, (ii)
assuming the consummation of the transactions contemplated thereby, any
Agreements and Instruments which would reasonably be expected to have a
Material Adverse Effect, (iii) any law, statute, rule or regulation
applicable to the Company or any Subsidiary or their respective assets
or properties or (iv) any judgment, order or decree of any domestic or
foreign court or governmental agency or authority having jurisdiction
over the Company or any Subsidiary or their respective assets or
properties. Assuming the accuracy of the representations and warranties
of the Initial Purchasers in Section 5(b) of this Agreement, no
consent, approval, authorization or order of, or filing, registration,
qualification, license or permit of or with, any court or governmental
agency, body or administrative agency, domestic or foreign, is required
to be obtained or made by each of the Company or any Subsidiary for the
execution, delivery and performance by each of the Company or any
Subsidiary of the Transaction Documents to which it is a party
including the consummation of any of the transactions contemplated
thereby, except (w) such as have been or will be obtained or made on or
prior to the Closing Date, (x) registration of the Exchange Offer or
resale of the Notes under the Act pursuant to the
-12-
Registration Rights Agreement or (y) qualification of the Indenture
under the Trust Indenture Act of 1939, as amended (the "Trust Indenture
Act"), in connection with the issuance of the Exchange Notes. No
consents or waivers from any other person or entity are required for
the execution, delivery and performance of this Agreement or any of the
other Transaction Documents or the consummation of any of the
transactions contemplated thereby, other than such consents and waivers
as have been obtained or will be obtained prior to the Closing Date.
(xviii) Except as set forth in the Offering Memorandum, there is
(A) no action, suit or proceeding before or by any court, arbitrator or
governmental agency, body or official, domestic or foreign, now pending
or, to the knowledge of the Company or any Subsidiary threatened or
contemplated, to which any of the Company or any Subsidiary is or may
be a party or to which the business, assets or property of such person
is or may be subject, (B) no statute, rule, regulation or order that
has been enacted, adopted or issued or, to the knowledge of the
Issuers, that has been proposed by any governmental body or agency,
domestic or foreign, (C) no injunction, restraining order or order of
any nature by a federal or state court or foreign court of competent
jurisdiction to which any of the Company or any Subsidiary is or may be
subject that (x) in the case of clause (A) above, would reasonably be
expected, either individually or in the aggregate, (1) to have a
Material Adverse Effect or (2) to interfere with the issuance of the
Notes in any jurisdiction or with the consummation of the transactions
contemplated by any of the Transaction Documents and (y) in the case of
clauses (B) and (C) above, would reasonably be expected, either
individually or in the aggregate, (1) to have a Material Adverse Effect
or (2) to interfere with the issuance of the Notes in any jurisdiction
or with the consummation of the transactions contemplated by any of the
Transaction Documents. Every request of any securities authority or
agency of any jurisdiction for additional information with respect to
the Notes that has been received by the Company or any Subsidiary or
their counsel prior to the date hereof has been, or will prior to the
Closing Date be, complied with in all material respects.
(xix) Except as would not reasonably be expected to have a
Material Adverse Effect, no labor disturbance by the employees of any
of the Company or the Subsidiaries exists or, to the knowledge of the
Issuers, is imminent.
(xx) Except as set forth or incorporated by reference in the
Offering Memorandum, the Company and each Subsidiary (A) is in
compliance with, or not subject to costs or liabilities under laws,
regulations, rules of common law, orders and decrees, as in effect as
of the date hereof, and any present judgments and injunctions issued or
promulgated thereunder relating to pollution or protection of public
and employee health and safety, the environment or hazardous or toxic
substances or wastes, pollutants or contaminants applicable to it or
its business or operations or ownership or use of its property
("Environmental Laws"), other than noncompliance or such costs or
liabilities that would not reasonably be expected to have a Material
Adverse Effect, and (B) possesses all permits, licenses or other
approvals required under applicable Environmental Laws, except where
the failure to possess any such permit, license or other approval would
not reasonably be expected to have, either individually or in the
aggregate, a Material Adverse Effect. All material currently pending
and, to the knowl-
-13-
edge of the Issuers, threatened proceedings, notices of violation,
demands, notices of potential responsibility or liability, suits and
existing environmental investigations by any governmental authority
which the Company or the Subsidiaries could reasonably expect to result
in a Material Adverse Effect are fully and accurately described in all
material respects in the Offering Memorandum The Company and each
Subsidiary maintains a system of internal environmental management
controls sufficient to provide reasonable assurance of compliance in
all material respects of its business facilities, real property and
operations with requirements of applicable Environmental Laws other
than where such non-compliance would not have a Material Adverse
Effect.
(xxi) The Company and each Subsidiary has (A) all licenses,
certificates, permits, authorizations, approvals, franchises and other
rights from, and has made all declarations and filings with, all
applicable authorities, all self-regulatory authorities and all courts
and other tribunals (each, an Authorization") necessary to engage in
the business conducted by it in the manner described in the Offering
Memorandum, except where failure to hold such Authorizations would not
be reasonably expected to have a Material Adverse Effect, and (B)
neither the Company nor any Subsidiary has received notice of any
proceedings relating to the limitation, suspension or revocation of any
such Authorization, except where such limitation, suspension or
revocation would not reasonably be expected to have a Material Adverse
Effect. All such Authorizations are valid and in full force and effect
and the Company and each Subsidiary is in compliance in all material
respects with the terms and conditions of all such Authorizations and
with the rules and regulations of the regulatory authorities having
jurisdiction with respect to such Authorizations, except for any
invalidity, failure to be in full force and effect or noncompliance
with any Authorization that would not reasonably be expected to have a
Material Adverse Effect.
(xxii) The Company and each Subsidiary has valid title in fee
simple to all items of real property and title to all personal property
necessary to conduct their business as currently conducted, in each
case free and clear of any pledge, lien, encumbrance, security interest
or other defect or claim of any third party, except (i) as created
pursuant to the Credit Facilities, (ii) such as do not materially and
adversely affect the value of such property and do not interfere with
the use made or proposed to be made of such property by the Company or
such Subsidiary to an extent that such interference would have a
Material Adverse Effect, and (iii) permitted liens set forth in the
Offering Memorandum. Any real property and buildings held under lease
by the Company or any such Subsidiary are held under valid, subsisting
and enforceable leases, with such exceptions as do not materially
interfere with the use made or proposed to be made of such property and
buildings by the Company or such Subsidiary.
(xxiii) The Company and each Subsidiary owns, possesses or has
the right to employ all patents, patent rights, licenses, inventions,
copyrights, know-how (including trade secrets and other unpatented
and/or unpatentable proprietary or confidential information, systems or
procedures), trademarks, service marks and trade names (collectively,
the "Intellectual Property") necessary to conduct the businesses
operated by it as described in the Offering Memorandum, except where
the failure to own, possess or have the right to employ such
Intellectual Property would not reasonably be expected to have a
Material Adverse Effect. None of the
-14-
Company or any Subsidiary has received any notice of infringement of or
conflict with (and neither knows of any such infringement or a conflict
with) asserted rights of others with respect to any of the foregoing
that, if such assertion of infringement or conflict were sustained,
would reasonably be expected to have a Material Adverse Effect. The use
of the Intellectual Property in connection with the business and
operations of the Company and the Subsidiaries does not infringe on the
rights of any person, except for such infringement as would not
reasonably be expected to have a Material Adverse Effect.
(xxiv) All tax returns required to be filed by the Company and
each Subsidiary have been filed in all jurisdictions where such returns
are required to be filed; and all taxes, including withholding taxes,
value added and franchise taxes, penalties and interest, assessments,
fees and other charges due pursuant to such returns or pursuant to any
assessment received by the Company or any Subsidiary have been paid,
other than those being contested in good faith and for which reserves
have been provided, if required in accordance with GAAP (as defined in
the Indenture) or those currently payable without penalty or interest
and except where the failure to make such required filings or payment
would not reasonably be expected to have a Material Adverse Effect. To
the knowledge of the Issuers, there are no material proposed additional
tax assessments against any of the Company and the Subsidiaries or
their assets or property.
(xxv) Neither the Company nor the Subsidiaries has any
liability for any prohibited transaction or accumulated funding
deficiency (within the meaning of Section 412 of the Code) or any
complete or partial withdrawal liability with respect to any pension,
profit sharing or other plan which is subject to the Employee
Retirement Income Security Act of 1974, as amended ("ERISA"), to which
the Company or any of the Subsidiaries makes or ever has made a
contribution and in which any employee of the Company or any of the
Subsidiaries is or has ever been a participant. With respect to such
plans, the Company and each of the Subsidiaries is in compliance in all
material respects with all applicable provisions of ERISA.
(xxvi) Neither the Company nor any Subsidiary is an
"investment company" or a company "controlled" by an "investment
company" incorporated in the United States within the meaning of the
Investment Company Act of 1940, as amended.
(xxvii) Other than affiliated physicians who have acquired
shares of common stock of the Company in connection with Consideration
Agreements, there are no holders of securities of the Company or any
Subsidiary who have the right to request or demand that the Company or
any Subsidiary register under the Act any of such securities held by
any such holder.
(xxviii) The Company and each Subsidiary maintain a system of
internal accounting controls sufficient to provide reasonable assurance
that: (A) transactions are executed in accordance with management's
general or specific authorizations; (B) transactions are recorded as
necessary to permit preparation of its financial statements in
conformity with GAAP and to maintain accountability for assets; (C)
access to assets is permitted only in accordance with management's
general or specific authorization; and (D) the recorded accountability
for its
-15-
assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences.
(xxix) The Company and each Subsidiary maintain insurance
covering its properties, assets, operations, personnel and businesses
of such type and in such amounts in accordance with customary industry
practice to protect the Company and the Subsidiaries and their
businesses.
(xxx) Neither the Company nor (to its knowledge) any of its
affiliates (as defined in Rule 501(b) of Regulation D under the Act)
has (A) taken, directly or indirectly, any action designed to, or that
might reasonably be expected to, cause or result in stabilization or
manipulation of the price of any security of the Issuers to facilitate
the sale or resale of the Original Notes or (B) sold, bid for,
purchased or paid any person any compensation for soliciting purchases
of the Original Notes in a manner that would require registration of
the Original Notes under the Act or paid or agreed to pay to any person
any compensation for soliciting another to purchase any other
securities of any Issuer in a manner that would require registration of
the Original Notes under the Act.
(xxxi) Neither the Company nor (to its knowledge) any of its
affiliates (as defined in Regulation D under the Act) has, directly or
through any agent (other than the Initial Purchasers or any affiliate
of the Initial Purchasers, as to which no representation is made),
sold, offered for sale, contracted to sell, pledged, solicited offers
to buy or otherwise disposed of or negotiated in respect of, any
security (as defined in the Act) that is currently or will be
integrated with the sale of the Original Notes in a manner that would
require the registration of the Original Notes under the Act.
(xxxii) None of the Issuers or (to their knowledge) any of
their affiliates, or any person acting on its or their behalf (other
than the Initial Purchasers, as to whom the Issuers make no
representation), is engaged in any directed selling effort with respect
to the Original Notes, and each of them has complied with the offering
restrictions requirement of Regulation S under the Act. Terms used in
this paragraph have the meaning given to them by Regulation S.
(xxxiii) No consent, approval, authorization or other order of,
or registration or filing with, any court or other governmental or
regulatory authority or agency is required for the Company's execution,
delivery and performance of the Transaction Documents or the issuance
and delivery of the Notes or the Exchange Notes, or consummation of the
transactions contemplated hereby and thereby and by the Offering
Memorandum (including, but not limited to, the obligations of the
Company to effect payments of principal of, and premium, interest and
Additional Interest (as defined in the Registration Rights Agreement)
if any, on the Notes and the Exchange Notes in United States dollars
free of any liability on the part of any holder thereof), except such
as have been obtained or made by the Issuers and are in full force and
effect and as may be required by federal and state securities laws with
respect to the Issuers' obligations under the Registration Rights
Agreement. No form of general solicitation or general advertising
(prohibited by the Act in connection with offers or sales such as the
Exempt Resales) was used by the Company or any of its representatives
(other than the Initial
-16-
Purchasers, as to whom the Issuers make no representation) in connection
with the offer and sale of any of the Original Notes or in connection with
Exempt Resales, including, but not limited to, articles, notices or other
communications published in any newspaper, magazine or similar medium or
broadcast over television or radio or displayed on any computer terminal,
or any seminar or meeting whose attendees have been invited by any general
solicitation or general advertising. Neither the Company nor any of its
affiliates has entered into, and neither the Company nor any of its
affiliates will enter into, any contractual arrangement with respect to the
distribution of the Original Notes except for this Agreement.
(xxxiv) As of September 30, 2001, neither the Company nor any
Subsidiary had any material liabilities or obligations, direct or
contingent, that were not set forth in the Company's consolidated balance
sheet as of such date or in the notes thereto set forth in the Offering
Memorandum. Since September 30, 2001, except as set forth or contemplated
in the Offering Memorandum, (a) neither the Company nor any Subsidiary has
(1) incurred any liabilities or obligations, direct or contingent, that
would reasonably be expected to have a Material Adverse Effect, or (2)
entered into any material transaction not in the ordinary course of
business, (b) there has not been any event or development with respect to
the business or condition (financial or other) of the Company and the
Subsidiaries that, either individually or in the aggregate, would
reasonably be expected to have a Material Adverse Effect, (c) there has
been no dividend or distribution of any kind declared, paid or made by the
Company on any class of its capital stock and (d) there has not been any
change in the long-term debt of the Company or any of the Subsidiaries.
(xxxv) Neither the Company nor any of the Subsidiaries (or any agent
thereof acting on their behalf) has taken, and none of them will take, any
action that might cause this Agreement or the issuance or sale of the Notes
to violate Regulation T, U or X of the Board of Governors of the Federal
Reserve System, as in effect, or as the same may hereafter be in effect, on
the Closing Date.
(xxxvi) PricewaterhouseCoopers LLP, with respect to the Company and its
Subsidiaries, and Arthur Andersen LLP, with respect to the 1998
consolidated financial statements of Physician Reliance Network, Inc.
incorporated by reference to the Offering Memorandum, are independent
accountants within the meaning of the Act. The historical financial
statements and the notes thereto included and incorporated by reference in
the Offering Memorandum present fairly in all material respects the
consolidated financial position and results of operations of the Company
and its Subsidiaries at the respective dates and for the respective periods
indicated. Such financial statements have been prepared in accordance with
GAAP applied on a consistent basis throughout the periods presented (except
as disclosed in the Offering Memorandum). The other historical financial
and statistical information and data included in the Offering Memorandum
are accurately presented in all material respects and prepared on a basis
consistent with the financial statements and the books and records of the
Company and its subsidiaries.
(xxxvii) The unaudited pro forma financial statements (including the
notes thereto) and the other pro forma financial information included in
the Offering Memorandum have been
-17-
properly computed on the bases described therein; subject to the
uncertainties set forth under "Business -- Service line structure --
Financial Impact of Repositioning," in the Offering Memorandum, the
assumptions used in the preparation of the pro forma financial data and
other pro forma financial information included in the Offering Memorandum
are reasonable in all material respects and the adjustments used therein
are appropriate in all material respects to give effect to the transactions
or circumstances referred to therein.
(xxxviii) As of the date hereof (immediately prior to and immediately
following the issuance of the Notes on such date) the Company and each of
the Subsidiaries is and will be Solvent. No Issuer is contemplating either
the filing of a petition by it under any bankruptcy or insolvency laws or
the liquidating of all or a substantial portion of its property, and the
Company has no knowledge of any Person contemplating the filing of any such
petition against any Issuer. As used herein, "Solvent" shall mean, for any
Person on a particular date, that on such date (a) the fair value of the
property of such Person is greater than the total amount of liabilities,
including, without limitation, contingent liabilities, of such Person, (b)
the present fair salable value of the assets of such Person is not less
than the amount that will be required to pay the probable liability of such
Person on its debts as they become absolute and matured, (c) such Person
does not intend to, and does not believe that it will, incur debts and
liabilities beyond such Person's ability to pay as such debts and
liabilities mature, (d) such Person is not engaged in a business or a
transaction, and is not about to engage in a business or a transaction, for
which such Person's property would constitute an unreasonably small capital
and (e) such Person is able to pay its debts as they become due and
payable.
(xxxix) Except as described in the section entitled "Plan of
Distribution" in the Offering Memorandum, there are no contracts,
agreements or understandings between the Company or any of its Subsidiaries
and any other person other than the Initial Purchasers that would give rise
to a valid claim against the Company, any such Subsidiary or the Initial
Purchasers for a brokerage commission, finder's fee or like payment in
connection with the issuance, purchase and sale of the Notes.
(xl) The statistical and market-related data and forward-looking
statements (within the meaning of Section 27A of the Act and Section 21E of
the Exchange Act) included in the Offering Memorandum are based on or
derived from sources that the Issuers believe to be reliable and accurate
in all material respects and represent their good faith estimates that are
made on the basis of data derived from such sources.
(xli) As of the Closing Date, each of the representations and
warranties of the Company and the Subsidiaries set forth in each of the
Transaction Documents will be true and correct as if made at and as of such
date (other than to the extent any such representation or warranty is
expressly made as to only a certain other date).
(xlii) Each certificate signed by any officer of the Issuers and
delivered to the Initial Purchasers or counsel for the Initial Purchasers
pursuant to, or in connection with, this Agreement shall be deemed to be a
representation and warranty by the Issuers to the Initial Purchasers as to
the matters covered by such certificate.
-18-
(xlii) The Company has delivered to the Initial Purchasers a true and
correct copy of each of the Transaction Documents, together with all
related agreements and all schedules and exhibits thereto, and there shall
have been no material amendments, alterations, modifications or waivers of
any of the provisions of any such documents since their respective dates of
execution, other than any such amendments, alterations, modifications and
waivers as to which the Initial Purchasers have been advised in writing and
which would be required to be disclosed in the Offering Memorandum; and to
the knowledge of the Company and the Subsidiaries there exists no event or
condition which would constitute a default or an event of default under any
of the Transaction Documents which would result in a Material Adverse
Effect or materially adversely affect the ability of the Company and the
Subsidiaries to consummate the Transactions.
The Issuers acknowledge that the Initial Purchasers and, for purposes
of the opinions to be delivered to the Initial Purchasers pursuant to Section 8
of this Agreement, counsel to the Issuers and counsel to the Initial Purchasers
will rely upon the accuracy and truth of the foregoing representations and the
Issuers hereby consent to such reliance.
(b) Each Initial Purchaser acknowledges that it is purchasing the
Original Notes pursuant to a private sale exemption from registration under the
Securities Act, and that the Original Notes have not been registered under the
Securities Act and may not be offered or sold within the United States or to, or
for the account or benefit of, U.S. persons except pursuant to an exemption from
the registration requirements of the Securities Act. Each Initial Purchaser
represents, warrants and covenants to the Issuers that:
(i) It is a QIB with such knowledge and experience in financial and
business matters as are necessary in order to evaluate the merits and risks
of an investment in the Notes.
(ii) (A) Neither it, nor any person acting on its behalf, has or will
solicit offers for, or offer or sell, the Original Notes by any form of
general solicitation or general advertising (as those terms are used in
Regulation D under the Act) or in any manner involving a public offering
within the meaning of Section 4(2) of the Act and (B) it has and will
solicit offers for the Original Notes only from, and will offer and sell
the Original Notes only to (1) persons whom such Initial Purchaser
reasonably believes to be QIBs or, if any such person is buying for one or
more institutional accounts for which such person is acting as fiduciary or
agent, only when such person has represented to the Initial Purchasers that
each such account is a QIB to whom notice has been given that such sale or
delivery is being made in reliance on Rule 144A, and, in each case, in
reliance on the exemption from the registration requirements of the Act
pursuant to Rule 144A, or (2) persons other than U.S. persons outside the
United States in reliance on the exemption from the registration
requirements of the Act provided by Regulation S.
(iii) With respect to offers and sales outside the United States:
(A) the Initial Purchasers will comply with all applicable
laws and regulations in each jurisdiction in which they acquire,
offer, sell or deliver Notes or have in
-19-
their possession or distribute either any Offering Memorandum or
any such other material, in all cases at their own expense; and
(B) the Initial Purchasers have offered the Original Notes
and will offer and sell the Original Notes (1) as part of its
distribution at any time and (2) otherwise until 40 days after
the later of the commencement of the offering of the Original
Notes and the Closing Date, only in accordance with Rule 903 of
Regulation S or another exemption from the registration
requirements of the Act. Accordingly, neither the Initial
Purchasers nor any persons acting on their behalf have engaged or
will engage in any directed selling efforts (within the meaning
of Regulation S) with respect to the Original Notes, and any such
persons have complied and will comply with the offering
restrictions requirements of Regulation S.
Terms used in this Section 5(b)(iii) have the meanings given to
them by Regulation S.
(iv) The source of funds being used by it to acquire the
Original Notes does not include the assets of any "employee benefit
plan" (within the meaning of Section 3 of ERISA) or any "plan" (within
the meaning of Section 4975 of the Code).
The Initial Purchasers understand that the Issuers and, for
purposes of the opinions to be delivered to them pursuant to Section 8 hereof,
counsel to the Issuers and counsel to the Initial Purchasers will rely upon the
accuracy and truth of the foregoing representations, and the Initial Purchasers
hereby consent to such reliance.
6. Indemnification. (a) Each of the Issuers, jointly and
---------------
severally, agrees to indemnify and hold harmless the Initial Purchasers, each
person, if any, who controls the Initial Purchasers within the meaning of
Section 15 of the Act or Section 20(a) of the Exchange Act, the agents,
employees, officers and directors of the Initial Purchasers and the agents,
employees, officers and directors of any such controlling person from and
against any and all losses, liabilities, claims, damages and expenses whatsoever
(including, but not limited, to reasonable attorneys' fees and any and all
reasonable expenses whatsoever incurred in investigating, preparing or defending
against any litigation, commenced or threatened, or any claim whatsoever, and
any and all reasonable amounts paid in settlement of any claim or litigation)
(collectively, "Losses") to which they or any of them may become subject under
the Act, the Exchange Act or otherwise insofar as such Losses (or actions in
respect thereof) arise out of or are based upon any untrue statement or alleged
untrue statement of a material fact contained in the Preliminary Offering
Memorandum or the Offering Memorandum, or in any supplement thereto or amendment
thereof, or arise out of or are based upon the omission or alleged omission to
state therein a material fact necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading; provided,
however, that the Issuers will not be liable to any Initial Purchaser in any
such case to the extent, but only to the extent, that any such Loss arises out
of or is based upon any such untrue statement or alleged untrue statement or
omission or alleged omission made therein in reliance upon and in conformity
with written information relating to such Initial Purchaser furnished to the
Company by or on behalf of the Initial Purchasers expressly for use therein,
provided, however, that with respect to any untrue statement or omission from
the Preliminary Offering Memorandum the indemnity agreement contained in this
Section 6(a) shall not in-
-20-
ure to the benefit of any Initial Purchaser to the extent that the sale to the
person asserting any such Loss was an initial resale by such Initial Purchaser
and any such Loss of or with respect to such Initial Purchaser results from the
fact that both (A) it is established in the proceeding related to such Losses
that, to the extent required by applicable law, a copy of the Offering
Memorandum was not sent or given to such person at or prior to the written
confirmation of the sale of the Notes to such person and (B) the untrue
statement in or omission from the Preliminary Offering Memorandum was corrected
in the Offering Memorandum, provided, however, that this subsection (B) shall
not affect any Initial Purchaser's rights under the indemnity agreement
contained in this Section 6(a) with respect to any Losses arising out of or
based upon any other untrue statement or omission or alleged untrue statement or
omission that was the subject of such proceeding and (C) such failure to so send
or give was not a result of non-compliance by the Issuers with the Issuers'
offering documentation delivery obligations in Section 4. This indemnity
agreement will be in addition to any liability that the Issuers may otherwise
have, including, but not limited to, liability under this Agreement.
(b) Each Initial Purchaser, severally and not jointly, agrees to
indemnify and hold harmless each Issuer, each person, if any, who controls each
Issuer within the meaning of Section 15 of the Act or Section 20(a) of the
Exchange Act, and each of their respective agents, employees, officers and
directors and the agents, employees, officers and directors of any such
controlling person from and against any Losses to which they or any of them may
become subject under the Act, the Exchange Act or otherwise insofar as such
Losses (or actions in respect thereof) arise out of or are based upon any untrue
statement or alleged untrue statement of a material fact contained in the
Preliminary Offering Memorandum or the Offering Memorandum, or in any amendment
thereof or supplement thereto, or arise out of or are based upon the omission or
alleged omission to state therein a material fact necessary to make the
statements therein, in the light of the circumstances under which they were
made, not misleading, in each case to the extent, but only to the extent, that
any such Loss arises out of or is based upon any untrue statement or alleged
untrue statement or omission or alleged omission made therein in reliance upon
and in conformity with information relating to the Initial Purchasers furnished
in writing to the Company by or on behalf of such Initial Purchaser expressly
for use therein. The Issuers and the Initial Purchasers acknowledge that the
information described in Section 9 is the only information furnished in writing
by the Initial Purchasers to the Issuers expressly for use in the Preliminary
Offering Memorandum or the Offering Memorandum.
(c) Promptly after receipt by an indemnified party under
subsection 6(a) or 6(b) above of notice of the commencement of any action, suit
or proceeding (collectively, an "action"), such indemnified party shall, if a
claim in respect thereof is to be made against the indemnifying party under such
subsection, notify each party against whom indemnification is to be sought in
writing of the commencement of such action (but the failure so to notify an
indemnifying party shall not relieve such indemnifying party from any liability
that it may have under this Section 6 except to the extent that it has been
prejudiced in any material respect by such failure). In case any such action is
brought against any indemnified party, and it notifies an indemnifying party of
the commencement of such action, the indemnifying party will be entitled to
participate in such action, and to the extent it may elect by written notice
delivered to the indemnified party promptly after receiving the aforesaid notice
from such indemnified party, to assume the defense of such action with counsel
satisfactory to such indemnified party. Notwithstanding the foregoing, the
indemnified party or parties shall have the right to employ its or their own
counsel in any such action, but the reasonable fees and expenses of
-21-
such indemnified party or parties unless (i) the employment of such counsel
shall have been authorized in writing by the indemnifying parties in connection
with the defense of such action, (ii) the indemnifying parties shall not have
employed counsel to take charge of the defense of such action within a
reasonable time after notice of commencement of the action, or (iii) the named
parties to such action (including any impleaded parties) include such
indemnified party and the indemnifying parties (or such indemnifying parties
have assumed the defense of such action), and such indemnified party or parties
shall have reasonably concluded that there may be defenses available to it or
them that are different from or additional to those available to one or all of
the indemnifying parties (in which case the indemnifying parties shall not have
the right to direct the defense of such action on behalf of the indemnified
party or parties), in any of which events such reasonable fees and expenses of
counsel shall be borne by the indemnifying parties. In no event shall the
indemnifying party be liable for the fees and expenses of more than one counsel
(together with appropriate local counsel) at any time for all indemnified
parties in connection with any one action or separate but substantially similar
or related actions arising in the same jurisdiction out of the same general
allegations or circumstances. An indemnifying party shall not be liable for any
settlement of any claim or action effected without its written consent which
consent may not be unreasonably withheld. Notwithstanding the foregoing
sentence, if at any time an indemnified party shall have requested an
indemnifying party to reimburse the indemnified party for fees and expenses of
counsel as contemplated by paragraph (a) or (b) of this Section 6, then the
indemnifying party agrees that it shall be liable for any settlement of any
proceeding effected without its written consent if (i) such settlement is
entered into more than 45 business days after receipt by such indemnifying party
of the aforesaid request, (ii) such indemnifying party shall not have reimbursed
the indemnified party in accordance with such request prior to the date of such
settlement and (iii) such indemnified party shall have given the indemnifying
party at least 45 days prior notice of its intention to settle. No indemnifying
party shall, without the prior written consent of the indemnified party, effect
any settlement of any pending or threatened proceeding in respect of which any
indemnified party is or could have been a party and indemnity could have been
sought hereunder by such indemnified party, unless such settlement includes an
unconditional release of such indemnified party from all liability on claims
that are the subject matter of such proceeding.
7. Contribution. In order to provide for contribution in circumstances
------------
in which the indemnification provided for in Section 6 of this Agreement is for
any reason held to be unavailable from the indemnifying party, or is
insufficient to hold harmless a party indemnified under Section 6 of this
Agreement, each indemnifying party shall contribute to the amount paid or
payable by such indemnified party as a result of such aggregate Losses (i) in
such proportion as is appropriate to reflect the relative benefits received by
the Issuers, on the one hand, and such Initial Purchaser, on the other hand,
from the offering of the Original Notes or (ii) if such allocation is not
permitted by applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to above but also the relative fault of the
Issuers, on the one hand, and the Initial Purchasers, on the other hand, in
connection with the statements or omissions that resulted in such Losses, as
well as any other relevant equitable considerations. The relative benefits
received by the Issuers, on the one hand, and the Initial Purchasers, on the
other hand, shall be deemed to be in the same proportion as (x) the total
proceeds from the offering of Original Notes (net of discounts and commissions
but before deducting expenses) received by the Issuers are to (y) the total
discount received by the Initial Purchasers as set forth in the table on the
cover page of the Offering Memorandum. The relative fault of the Issuers, on
-22-
the one hand, and such Initial Purchaser, on the other hand, shall be determined
by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Issuers or the Initial
Purchasers and the parties' relative intent, knowledge, access to information
and opportunity to correct or prevent such statement or omission or alleged
statement or omission.
The Issuers and the Initial Purchasers agree that it would not be just
and equitable if contribution pursuant to this Section 7 were determined by pro
rata allocation or by any other method of allocation that does not take into
account the equitable considerations referred to above. Notwithstanding the
provisions of this Section 7, (i) in no case shall any Initial Purchaser be
required to contribute any amount in excess of the amount by which the total
discount applicable to the Original Notes pursuant to this Agreement exceeds the
amount of any damages that such Initial Purchaser has otherwise been required to
pay by reason of any untrue or alleged untrue statement or omission or alleged
omission and (ii) no person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Act) shall be entitled to contribution from any
person who was not guilty of such fraudulent misrepresentation. For purposes of
this Section 7, each person, if any, who controls the Initial Purchasers within
the meaning of Section 15 of the Act or Section 20(a) of the Exchange Act shall
have the same rights to contribution as the Initial Purchasers, and each person,
if any, who controls any Issuer within the meaning of Section 15 of the Act or
Section 20(a) of the Exchange Act and each director, officer, employee and agent
of such Issuer shall have the same rights to contribution such Issuer. Any party
entitled to contribution will, promptly after receipt of notice of commencement
of any action against such party in respect of which a claim for contribution
may be made against another party or parties under this Section 7, notify such
party or parties from whom contribution may be sought, but the omission to so
notify such party or parties shall not relieve the party or parties from whom
contribution may be sought from any obligation it or they may have under this
Section 7 or otherwise, except to the extent that it has been prejudiced in any
material respect by such failure; provided, however, that no additional notice
shall be required with respect to any action for which notice has been given
under Section 6 for purposes of indemnification. Anything in this section to the
contrary notwithstanding, no party shall be liable for contribution with respect
to any action or claim settled without its written consent, provided, however,
that such written consent was not unreasonably withheld.
8. (a) Conditions of Initial Purchasers' Obligations. The
---------------------------------------------
obligations of the Initial Purchasers to purchase and pay for the Original
Notes, as provided for in this Agreement, shall be subject to satisfaction of
the following conditions prior to or concurrently with such purchase:
(i) All of the representations and warranties of the Issuers contained
in this Agreement shall be true and correct, or true and correct in all
material respects where such representations and warranties are not
qualified by materiality or Material Adverse Effect, on the date of this
Agreement and, in each case after giving effect to the transactions
contemplated hereby, on the Closing Date, except that if a representation
and warranty is made as of a specific date, and such date is expressly
referred to therein, such representation and warranty shall be true and
correct (or true and correct in all material respects, as applicable) as of
such date. The Issuers shall have performed or complied with all of the
agreements and covenants
-23-
contained in this Agreement and required to be performed or complied with
by them at or prior to the Closing Date.
(ii) The Offering Memorandum shall have been printed and copies
distributed to the Initial Purchasers on the day following the date of this
Agreement or at such later date as the Initial Purchasers may determine. No
stop order suspending the qualification or exemption from qualification of
the Original Notes in any jurisdiction shall have been issued and no
proceeding for that purpose shall have been commenced or shall be pending
or threatened.
(iii) No action shall have been taken and no statute, rule, regulation
or order shall have been enacted, adopted or issued by any governmental
agency that would, as of the Closing Date, prevent the issuance of the
Original Notes or consummation of the Exchange Offer; except as disclosed
in the Offering Memorandum, no action, suit or proceeding shall have been
commenced and be pending against or affecting or, to the knowledge of the
Issuers, threatened against the Company and/or any Subsidiary before any
court or arbitrator or any governmental body, agency or official that would
reasonably be expected to have a Material Adverse Effect; and no stop order
preventing the use of the Preliminary Offering Memorandum or the Offering
Memorandum, or any amendment or supplement thereto, or any order asserting
that any of the transactions contemplated by this Agreement are subject to
the registration requirements of the Act shall have been issued.
(iv) As of September 30, 2001, neither the Company nor any Subsidiary
had any material liabilities or obligations, direct or contingent, that
were not set forth in the Company's consolidated balance sheet as of such
date or in the notes thereto set forth in the Offering Memorandum. Since
September 30, 2001, except as set forth or contemplated in the Offering
Memorandum, (a) neither the Company nor any Subsidiary has (1) incurred any
liabilities or obligations, direct or contingent, that would reasonably be
expected to have a Material Adverse Effect, or (2) entered into any
material transaction not in the ordinary course of business, (b) there has
not been any event or development in respect of the business or condition
(financial or other) of the Company and the Subsidiaries that, either
individually or in the aggregate, would reasonably be expected to have a
Material Adverse Effect and (c) there has been no dividend or distribution
of any kind declared, paid or made by the Company on any class of its
capital stock.
(v) The Initial Purchasers shall have received certificates, dated
the Closing Date, signed by two authorized officers of each of the Company
and the Guarantors confirming, as of the Closing Date, to their knowledge,
the matters set forth in paragraphs (i), (ii), (iii) and (iv) of this
Section 8.
(vi) The Initial Purchasers shall have received on the Closing Date
opinions dated the Closing Date, addressed to the Initial Purchasers, of
(A) Andrews & Kurth, Mayor, Day, Caldwell & Keeton L.L.P., counsel to the
Issuers, (B) Jenkens & Gilchrist, a professional corporation, special
regulatory counsel for the Company, and (C) Phillip H. Watts, general
counsel for the Company substantially in the form of Exhibits A-1, A-2 and
------------ ---
A-3, respectively,
---
-24-
attached hereto and in form and substance reasonably satisfactory to the
Initial Purchasers and counsel to the Initial Purchasers.
(vii) The Initial Purchasers shall have received on the Closing Date
an opinion (satisfactory in form and substance to the Initial Purchasers)
dated the Closing Date of Cahill Gordon & Reindel, counsel to the Initial
Purchasers.
(viii) The Initial Purchasers shall have received a "comfort letter"
from PricewaterhouseCoopers LLP and Arthur Andersen LLP, independent public
accountants for the Company, dated the date of this Agreement, addressed to
the Initial Purchasers and in form and substance satisfactory to the
Initial Purchasers and counsel to the Initial Purchasers. In addition, the
Initial Purchasers shall have received a "bring-down comfort letter" from
PricewaterhouseCoopers LLP, dated as of the Closing Date, addressed to the
Initial Purchasers and in form and substance satisfactory to the Initial
Purchasers and counsel to the Initial Purchasers.
(ix) Each of the Issuers shall have entered into the Indenture and
each of the Initial Purchasers shall have received copies, conformed as
executed, thereof.
(x) Each of the Issuers shall have entered into the Credit
Facilities and each of the Initial Purchasers shall have received
counterparts, conformed as executed, thereof.
(xi) Each of the Issuers shall have entered into the Registration
Rights Agreement and each of the Initial Purchasers shall have received
counterparts, conformed as executed, thereof.
(xii) The Company shall have notified the lenders under the Company's
credit agreement dated as of December 30, 1997, as amended (as in effect on
the date hereof), of the Company's intention to pay all obligations with
respect thereto with a portion of the proceeds of the Original Notes and
simultaneously with the issuance of the Original Notes all such obligations
shall be paid by the Company in full. Upon such payment, such credit
agreement shall be terminated in accordance with the terms thereof.
(xiii) The Initial Purchasers shall have received on the Closing Date
a certificate from the Company dated the Closing Date as to the solvency of
the Company and the Subsidiaries, addressed to the Initial Purchasers.
(xiv) The Initial Purchasers shall have received copies of the
Guarantees conformed as executed.
(xv) All government authorizations required in connection with the
issue and sale of the Notes as contemplated under this Agreement and the
performance of the Company's obligations hereunder and under the Indenture
and the Notes shall be in full force and effect.
(xvi) The Initial Purchasers shall have been furnished with wiring
instructions for the application of the proceeds of the Original Notes in
accordance with this Agreement and such other information as it may
reasonably request.
-25-
(xvii) Cahill Gordon & Reindel, counsel to the Initial Purchasers,
shall have been furnished with such documents as they may reasonably
request to enable them to review or pass upon the matters referred to in
this Section 8 and in order to evidence the accuracy, completeness or
satisfaction in all material respects of any of the representations,
warranties or conditions contained in this Agreement.
(xviii) The Original Notes shall be eligible for trading in the Portal
market upon issuance.
(xix) All agreements set forth in the representation letter of the
Issuers to DTC relating to the approval of the Notes by DTC for
"book-entry" transfer shall have been complied with.
If any of the conditions specified in this Section 8 (a) shall not
have been fulfilled in all material respects when and as required by this
Agreement to be fulfilled (or waived by the Initial Purchasers), this Agreement
may be terminated by the Initial Purchasers on notice to the Company at any time
at or prior to the Closing Date, and such termination shall be without liability
of any party to any other party. Notwithstanding any such termination, the
provisions of Sections 4(f), 6, 7, 9, 10 and 11(d) shall remain in effect.
(b) Condition of the Issuers' Obligations. The obligations of the
-------------------------------------
Issuers to issue and sell the Original Notes, as provided for in this Agreement,
shall be subject to satisfaction of the following condition prior to or
concurrently with such issuance or sale:
(i) Each of the Issuers shall have entered into the Credit
Facilities and each of the Initial Purchasers shall have received counterparts,
conformed as executed, thereof.
The documents required to be delivered by this Section 8 will be
delivered at the office of counsel for the Initial Purchasers on the Closing
Date.
9. Initial Purchasers' Information. The Issuers and the Initial
-------------------------------
Purchasers severally acknowledge that the statements with respect to the
delivery of the Original Notes to the Initial Purchasers set forth in (x) the
third paragraph on page (ii) and (y) the fourth paragraph, the sixth paragraph,
the seventh paragraph, the first, second and third sentences of the eighth
paragraph, the ninth paragraph and the eleventh paragraph under the caption
"Plan of Distribution" in the Preliminary Offering Memorandum and the Offering
Memorandum constitute the only information furnished in writing by the Initial
Purchasers expressly for use in the Preliminary Offering Memorandum or the
Offering Memorandum.
10. Survival of Representations and Agreements. All
------------------------------------------
representations and warranties, covenants and agreements contained in this
Agreement, including the agreements contained in Sections 4(f) and 11(d), the
indemnity agreements contained in Section 6 and the contribution agreements
contained in Section 7 shall remain operative and in full force and effect
regardless of any investigation made by or on behalf of the Initial Purchasers
or any controlling person thereof or by or on behalf of the Issuers or any
controlling person thereof, and shall survive delivery of and payment for
-26-
the Original Notes to and by the Initial Purchasers. The agreements contained in
Sections 4(f), 6, 7, 9 and 11(d) shall survive the termination of this
Agreement, including pursuant to Section 11.
11. Effective Date of Agreement; Termination. (a) This Agreement
----------------------------------------
shall become effective upon execution and delivery of a counterpart hereof by
each of the parties hereto.
(b) The Initial Purchasers shall have the right to terminate this
Agreement at any time prior to the Closing Date by notice to the Company from
the Initial Purchasers, without liability (other than with respect to Sections 6
and 7) on the Initial Purchasers' part to the Issuers if, on or prior to such
date, (i) the Issuers shall have failed, refused or been unable to perform in
any material respect any agreement on its part to be performed under this
Agreement when and as required, (ii) any other condition to the obligations of
the Initial Purchasers under this Agreement to be fulfilled by the Issuers
pursuant to Section 8 (a) is not fulfilled when and as required in any material
respect, (iii) the condition to the obligations of the Issuers set forth in
Section 8(b)(i) is not fulfilled (iv) trading in securities of the Issuer on the
Nasdaq National Market shall have been suspended or materially limited, (v)
trading in securities generally on the New York Stock Exchange, the American
Stock Exchange or the Nasdaq National Market shall have been suspended or
materially limited, or minimum prices shall have been established thereon by the
Commission, or by such exchange or other regulatory body or governmental
authority having jurisdiction, (vi) a general banking moratorium shall have been
declared by federal or New York authorities, (vii) there shall have been a
material disruption in commercial banking or securities settlement or clearance
services in the United States, (viii) there is an outbreak or escalation of
hostilities or other national or international calamity, in any case involving
the United States, on or after the date of this Agreement, or if there has been
a declaration by the United States of a national emergency or war or other
national or international calamity or crisis (economic, political, financial or
otherwise) which affects the U.S. or international markets, making it, in the
Initial Purchasers' judgment, impracticable or inadvisable to proceed with the
offering or delivery of the Original Notes on the terms and in the manner
contemplated in the Offering Memorandum or (ix) there shall have been such a
change in general economic, political or financial conditions or the effect (or
potential effect if the financial markets in the United States have not yet
opened) of international conditions on the financial markets in the United
States shall be such as, in the Initial Purchasers' judgment, to make it
impracticable or inadvisable to proceed with the offering or delivery of the
Notes on the terms and in the manner contemplated in the Offering Memorandum.
(c) Any notice of termination pursuant to this Section 11 shall
be given at the address specified in Section 12 below by telephone, telex,
telephonic facsimile or telegraph, confirmed in writing by letter.
(d) If this Agreement shall be terminated pursuant to clause (i)
or (ii) of Section 11(b), or if the sale of the Notes provided for in this
Agreement is not consummated (x) because of any refusal, inability or failure on
the part of the Issuers to satisfy any condition to the obligations of the
Initial Purchasers set forth in this Agreement to be satisfied on their part,
(y) because of any refusal, inability or failure of the Issuers to issue and
sell the Notes as a result of the condition to the Issuers' obligations set
forth in clause (i) of Section 8(b) not being satisfied, or (z) because of any
refusal, inability or failure on the part of the Issuers to perform any
agreement in this Agreement or comply with any provision of this Agreement, the
Issuers will, subject to demand by the Initial Pur-
-27-
chasers, reimburse the Initial Purchasers for all of their reasonable
out-of-pocket expenses (including the fees and expenses of the Initial
Purchasers' counsel) incurred in connection with this Agreement.
12. Notice. All communications with respect to or under this
------
Agreement, except as may be otherwise specifically provided in this Agreement,
shall be in writing and, if sent to the Initial Purchasers, shall be mailed,
delivered, or, telegraphed or telecopied and confirmed in writing to UBS Warburg
LLC, 299 Park Avenue, New York, New York 10171 (telephone: (212) 821-3000, fax
number: 203-719-1075), Attention: Syndicate Department; and if sent to the
Issuers, shall be mailed, delivered or, telegraphed or telecopied and confirmed
in writing to US Oncology, Inc., 16825 Northchase Drive, Suite 1300, Houston,
Texas 77060 (telephone: (832) 601-8766, fax: (832) 601-6600), Attention: Chief
Executive Officer.
All such notices and communications shall be deemed to have been
duly given: when delivered by hand, if personally delivered; five business days
after being deposited in the mail, postage prepaid, if mailed; when receipt
acknowledged by telecopier machine, if telecopied; and one business day after
being timely delivered to a next-day air courier.
13. Parties. This Agreement shall inure solely to the benefit of,
-------
and shall be binding upon, the Initial Purchasers, the Issuers and the
controlling persons and agents referred to in Sections 6 and 7, and their
respective successors and assigns, and no other person shall have or be
construed to have any legal or equitable right, remedy or claim under or in
respect of or by virtue of this Agreement or any provision herein contained. The
term "successors and assigns" shall not include a purchaser, in its capacity as
such, of Notes from the Initial Purchasers.
14. Construction. This Agreement shall be construed in accordance
------------
with the internal laws of the State of New York (without giving effect to any
provisions thereof relating to conflicts of law).
15. Captions. The captions included in this Agreement are
--------
included solely for convenience of reference and are not to be considered a part
of this Agreement.
16. Counterparts. This Agreement may be executed in various
------------
counterparts that together shall constitute one and the same instrument.
If the foregoing Purchase Agreement correctly sets forth the
understanding among the Issuers and the Initial Purchasers, please so indicate
in the space provided below for the purpose, whereupon this letter and your
acceptance shall constitute a binding agreement among the Issuers and the
Initial Purchasers.
US ONCOLOGY, INC.
By: ______________________________________
Name:
Title:
The GUARANTORS listed on Schedule I hereto
By: ______________________________________
Name:
Title:
Confirmed and accepted as of
the date first above written:
UBS WARBURG LLC
By: ______________________________________
Name:
Title:
By: ______________________________________
Name:
Title:
DEUTSCHE BANC ALEX. BROWN INC.
By: ______________________________________
Name:
Title:
By: ______________________________________
Name:
Title:
FIRST UNION SECURITIES, INC.
By: ______________________________________
Name:
Title:
By: ______________________________________
Name:
Title:
Schedule I
Guarantors
AOR Holding Company of Indiana, Inc.
AOR Management Company of Alabama, Inc.
AOR Management Company of Arizona, Inc.
AOR Management Company of Central Florida, Inc.
AOR Management Company of Florida, Inc.
AOR Management Company of Indiana, Inc.
AOR Management Company of Missouri, Inc.
AOR Management Company of Nevada, Inc.
AOR Management Company of New York, Inc.
AOR Management Company of North Carolina, Inc.
AOR Management Company of Ohio, Inc.
AOR Management Company of Oklahoma, Inc.
AOR Management Company of Oregon, Inc.
AOR Management Company of Pennsylvania, Inc.
AOR Management Company of South Carolina, Inc.
AOR Management Company of Texas, Inc.
AOR Management Company of Virginia, Inc.
AOR of Indiana Management Partnership
AOR of Texas Management Limited Partnership
AOR Real Estate, Inc.
AOR Synthetic Real Estate, Inc.
AORIP, Inc.
AORT Holding Company, Inc.
Greenville Radiation Care, Inc.
Physician Reliance Holdings, LLC
Physician Reliance Network, Inc.
Physician Reliance, L.P.
PRN Physician Reliance, LLC
RMCC Cancer Center, Inc.
TOPS Pharmacy Services, Inc.
US Oncology Corporate, Inc.
US Oncology Research, Inc.
Schedule II
Jurisdiction
% of
Owned by the Incorporation
Subsidiary Type of Entity Company or Organization
---------- -------------- ------------ ---------------
AOR Holding Company of Corporation 100% owned by Physician Delaware
Indiana, Inc. Reliance Network, Inc.
AOR Management Company Corporation 100% owned by Physician Delaware
of Arizona, Inc. Reliance Network, Inc.
AOR Management Company Corporation 100% owned by Physician Delaware
of Indiana, Inc. Reliance Network, Inc.
AOR Management Company Corporation 100% owned by Physician Delaware
of New York, Inc. Reliance Network, Inc.
AOR Management Company Corporation 100% owned by Physician Delaware
of Oklahoma, Inc. Reliance Network, Inc.
AOR Management Company Corporation 100% owned by Physician Delaware
of Oregon, Inc. Reliance Network, Inc.
AOR Management Company Corporation 100% owned by Physician Delaware
of Pennsylvania, Inc. Reliance Network, Inc.
AOR Management Company Corporation 100% owned by Physician Delaware
of South Carolina, Inc. Reliance Network, Inc.
AOR Management Company Corporation 100% owned by Physician Delaware
of Virginia, Inc. Reliance Network, Inc.
AOR Management Company Corporation 100% owned by Physician Delaware
of North Carolina, Inc. Reliance Network, Inc.
AOR of Texas Management Limited Partnership 99% owned by AORT Holding Texas
Limited Partnership Company, Inc.; 1% owned by
AOR Management Company of
Texas, Inc.
AORT Holding Company, Corporation 100% owned by Physician Delaware
Inc. Reliance Network, Inc.
Jurisdiction
% of
Owned by the Incorporation
Subsidiary Type of Entity Company or Organization
---------- -------------- ------------ ---------------
Physician Reliance Network, Corporation 100% owned by US Oncology, Inc. Texas
Inc.
Physician Reliance Holdings, Limited Liability 100% owned by Physician Delaware
LLC Company Reliance Network, Inc.
Physician Reliance, L.P. Limited Partnership 99% owned by Physician Texas
Reliance Holdings, LLC; 1%
owned by PRN Physician
Reliance, LLC
RMCC Cancer Center, Inc. Corporation 100% owned by Physician Delaware
Reliance Network, Inc.
Schedule III
- --------------------------------------------------------------------------------
Principal Amount of
Initial Purchaser Original Notes
- --------------------------------------------------------------------------------
UBS Warburg LLC $ 61,250,000
- --------------------------------------------------------------------------------
Deutsche Banc Alex. Brown Inc. $ 56,875,000
- --------------------------------------------------------------------------------
First Union Securities, Inc. $ 35,000,000
- --------------------------------------------------------------------------------
J.P. Morgan Securities Inc. $ 21,875,000
- --------------------------------------------------------------------------------
Total $ 175,000,000
- --------------------------------------------------------------------------------